Publications 2005

PUBLICATIONS:

Fetterly GJ, Ong CM, Bhavnani SM, Loutit JS, Porter SB, Morello LG, Ambrose PG, Nicolau DP. Pharmacokinetics of oritavancin in plasma and skin blister fluid following administration of a 200-milligram dose for 3 days or a single 800-milligram dose. Antimicrob Agents Chemother. 2005 Jan;49(1):148-52.

Meagher AK, Ambrose PG, Grasela TH, Ellis-Grosse EJ. Pharmacokinetic/pharmacodynamic profile for tigecycline-a new glycylcycline antimicrobial agent. Diagn Microbiol Infect Dis. 2005 Jul;52(3):165-71.

Meagher AK, Ambrose PG, Grasela TH, Ellis-Grosse EJ. The pharmacokinetic and pharmacodynamic profile of tigecycline. Clin Infect Dis. 2005 Sep 1;41 Suppl 5:S333-40

Grasela TH, Fiedler-Kelly J, Walawander CA, Owen JS, Cirincione BB, Reitz KE, Ludwig EA, Passarell JA, Dement CW. Challenges in the Transition to Model-Based Development. The AAPS Journal. 2005 7(2): Article 49:E488-95.

Owens RC Jr, Ambrose PG.Antimicrobial Safety: Focus On Fluoroquinolones. 2005;41(S2):S144-57.

Meagher AK, Ambrose PG, Grasela TH, Ellis-Grosse EJ. The Pharmacokinetic And Pharmacodynamic Profile Of Tigecycline. 2005;41(S5):S333-40.

Meagher AK, Ambrose PG, Grasela TH, Ellis-Grosse EJ. Pharmacokinetic/Pharmacodynamic Profile For Tigecycline-A New Glycylcycline Antimicrobial Agent. 2005;52(3):165-71.

Grasela TH, Fiedler-Kelly J, Walawander CA, Owen JS, Cirincione BB, Reitz KE, Ludwig EA, Passarell JA, Dement CW. Challenges In The Transition To Model-Based Development. 2005;7(2):E488-95.

Fetterly GJ, Ong CM, Bhavnani SM, Loutit JS, Porter SB, Morello LG, Ambrose PG, Nicolau DP. Pharmacokinetics Of Oritavancin In Plasma And Skin Blister Fluid Following Administration Of A 200-Milligram Dose For 3 Days Or A Single 800-Milligram Dose. 2005;49(1):148-52.

Bhavnani SM, Hammel JP, Jones RN, Ambrose PG. Relationship Between Increased Levofloxacin Use And Decreased Susceptibility Of Streptococcus Pneumoniae In The United States. 2005;51(1):31-7.

Bhavnani SM, Hammel JP, Cirincione BB, Wikler MA, Ambrose PG. Use Of Pharmacokinetic-Pharmacodynamic Target Attainment Analyses To Support Phase 2 And 3 Dosing Strategies For Doripenem. 2005;49(9):3944-7.

Booker BM, Smith PF, Forrest A, Bullock J, Kelchlin P, Bhavnani SM, Jones RN, Ambrose PG. Application Of An In Vitro Infection Model And Simulation For Reevaluation Of Fluoroquinolone Breakpoints For Salmonella Enterica Serotype Typhi. 2005;49(5):1775-81.

Owens RC Jr, Bhavnani SM, Ambrose PG. Assessment Of Pharmacokinetic-Pharmacodynamic Target Attainment Of Gemifloxacin Against Streptococcus Pneumoniae. 2005;51(1):45-9.